Annual Pilot Funding
Changes coming to CTSC Annual Pilot
The new Annual Pilot RFA will reflect the changes as delineated in the most recent CTSA funding opportunity announcement (FOA)
The new Annual Pilot RFA will reflect the changes in the CTSA FOA (PAR-15-304), specifically, that the Pilots must not support any clinical trials beyond phase IIA. Each CTSA hub has the flexibility to focus and design their translational pilot program to address their particular priorities; however, the program should not exclusively focus on a select disease category, a few diseases or specialties, or on a limited number of investigators. The focus should be translational and clinical research rather than on basic discovery research.
Please stay tuned for more information regarding changes to the CTSC Annual Pilot RFA!
- Up to $50,000 per project for up to one year of support
The CTSC Annual Pilot Program is for researchers to conduct innovative translational research projects focused on the invention, preclinical development and/or first in man studies of novel therapeutic agents, biomedical devices, and diagnostics designed to address unmet clinical needs. Funding is intended to facilitate development of enabling technologies; new therapeutic, diagnostic or outcomes assessment approaches and/or device; novel cross-disciplinary collaborative programs; and promote research in the community. Research which may create intellectual property is encouraged. If funding would enhance an existing non-federally funded project or enable a proposal to a federal agency for use of CTSC and CCTRP resources, the application would be considered. This pilot has few restrictions and allows for the hiring of personnel. Researchers new to clinical research, clinical research scholars, or experienced researchers who are moving into a new area of research are strongly encouraged to apply.
Case Coulter Translational Research Partnership
In conjunction with the annual pilot, the Coulter-CCTRP component focuses on projects that may ultimately achieve translation to patients via product development and/or commercialization of intellectual property, and must have a biomedical engineering faculty member as a co-investigator to be eligible for this funding.
The mission of the Annual and CCTRP pilot program is to transform translational research not only by providing funding, but also by promoting basic and clinical investigator collaboration, increasing effective collaborations between biomedical engineers and clinicians, supporting the movement of promising technologies to clinical application, and providing access to valuable core technologies and services in a collaborative and service-oriented fashion.
Principal Investigator must have a primary appointment at Case Western Reserve University, Cleveland Clinic, MetroHealth Medical Center, University Hospitals Case Medical Center or The Louis Stokes Cleveland VA Medical Center and must be eligible as to submit an application to a larger source of federal or non-federal support.
Applications should be submitted through Webgrants at http://webgrants.case.edu/.
The Letter of Intent submission deadline is 11:59pm on January 15th (or the first following Monday if January 15th falls on a Saturday or Sunday). Investigators will be invited to apply for the funding based on the letters of intent and will need to submit full applications by March 15th.